Loading
PDBj
MenuPDBj@FacebookPDBj@X(formerly Twitter)PDBj@BlueSkyPDBj@YouTubewwPDB FoundationwwPDBDonate
RCSB PDBPDBeBMRBAdv. SearchSearch help

4K8B

Crystal structure of HCV NS3/4A protease complexed with inhibitor

Summary for 4K8B
Entry DOI10.2210/pdb4k8b/pdb
Related PRD IDPRD_001064
DescriptorNS3 protease, Nonstructural protein, ZINC ION, ... (6 entities in total)
Functional Keywordsprotease, hydrolase-hydrolase inhibitor complex, hydrolase/hydrolase inhibitor
Biological sourceHepatitis C virus
More
Total number of polymer chains4
Total formula weight42407.13
Authors
Nar, H. (deposition date: 2013-04-18, release date: 2014-03-26, Last modification date: 2023-11-08)
Primary citationLaplante, S.R.,Nar, H.,Lemke, C.T.,Jakalian, A.,Aubry, N.,Kawai, S.H.
Ligand bioactive conformation plays a critical role in the design of drugs that target the hepatitis C virus NS3 protease.
J.Med.Chem., 57:1777-1789, 2014
Cited by
PubMed Abstract: A ligand-focused strategy employed NMR, X-ray, modeling, and medicinal chemistry to expose the critical role that bioactive conformation played in the design of a variety of drugs that target the HCV protease. The bioactive conformation (bound states) were determined for key inhibitors identified along our drug discovery pathway from the hit to clinical compounds. All adopt similar bioactive conformations for the common core derived from the hit peptide DDIVPC. A carefully designed SAR analysis, based on the advanced inhibitor 1 in which the P1 to P3 side chains and the N-terminal Boc were sequentially truncated, revealed a correlation between affinity and the relative predominance of the bioactive conformation in the free state. Interestingly, synergistic conformation effects on potency were also noted. Comparisons with clinical and recently marketed drugs from the pharmaceutical industry showed that all have the same core and similar bioactive conformations. This suggested that the variety of appendages discovered for these compounds also properly satisfy the bioactive conformation requirements and allowed for a large variety of HCV protease drug candidates to be designed.
PubMed: 24144444
DOI: 10.1021/jm401338c
PDB entries with the same primary citation
Experimental method
X-RAY DIFFRACTION (2.8 Å)
Structure validation

246704

PDB entries from 2025-12-24

PDB statisticsPDBj update infoContact PDBjnumon